米非司酮配伍与不配伍内美通治疗子宫肌瘤临床探讨

目的探讨米非司酮配伍与不配伍内美通治疗子宫肌瘤的临床效果。方法将绝经前有症状的子宫肌瘤患者200例随机分成两组,A组米非司酮组,100例,每天口服米非司酮25mg;B组为米非司酮配伍内美通组,100例,每天口服米非司酮25mg,同时口服内美通2.5mg,每周2次,连服3个月。治疗前后B超测量子宫体积、肌瘤体积;行子宫内膜病检观察子宫内膜变化;检测雌、孕激素水平,血红蛋白,肝肾功能,观察服药后的副反应。结果两组患者治疗期间均闭经,子宫内膜及雌孕激素水平维持于增殖早期,血红蛋白上升。两组治疗后子宫体积、最大肌瘤的平均体积缩小。治疗后两组之间有显著性差异(P<0.01),B组子宫和最大肌瘤的体积缩小更明显。结论米非司酮配伍与不配伍内美通治疗子宫肌瘤均有较好的临床效果,米非司酮配伍内美通是更有效、更合理的方法。

Clinical exploration of mifepristone with or without gestrinone in the treatment of uterine leiomyoma

Objective To investigate the efficacy of mifepristone with or without gestrinone in the treatment of leiomyomas.Methods 200 symptomatic patients with leiomyomas were divided into 2 groups randomly.Group A(100 cases) received mifepristone 25mg per day;Group B(100 cases)received mifepristone per day combined with gestrinone 2.5mg twice a week for 3 months.Leiomyoma and uterine size were measured by B ultrasound,the changes of endometrium were examined pathologically.Estrogen and progesterone levels,hemoglobin and liver renal function were all measured,meanwhile,adverse effects of drugs were assessed.Results All the patients in the 2 groups were amenorrhea with increased hemoglobin,the level of estrogen and progesterone remained in the early stage of proliferation phase.The uterus and leiomyoma size in 2 gruops both reduced,but those in group B reduced less significantly(P<0.01).Conclusion Both mifepristone and mifepristone combined with gestrinone show good efficacy in the treatment of leiomyoma,but mifepristone combined with gestrinone is more suitable.